You are here

Can-Fite BioPharma

Spotlight – What is next in Nash

Spotlight – What is next in Nash

EP Vantage

clinical trials

Arrowhead Pharmaceuticals

Can-Fite BioPharma

Hepagene Therapeutics

Ligand Pharmaceuticals

Madrigal Pharmaceuticals

NGM Biopharmaceuticals

NorthSea Therapeutics

Sagimet Biosciences

Terns Pharmaceuticals

Viking Therapeutics

Flag link:

After a delay, Can-Fite digs into subpopulation data as liver cancer drug fails to hit primary endpoint

After a delay, Can-Fite digs into subpopulation data as liver cancer drug fails to hit primary endpoint

Fierce Biotech

Can-Fite BioPharma

clinical trials

Flag link:

Top 6 Biotech Movers From The Past Week

Top 6 Biotech Movers From The Past Week

24/7 Wall St

Can-Fite BioPharma

Intra-Cellular Therapies

Raptor Pharmaceuticals

TRACON Pharmaceuticals

Flag link:

FDA Grants Fast Track Designation to Can-Fite's CF102 in the Treatment of Liver Cancer

FDA Grants Fast Track Designation to Can-Fite's CF102 in the Treatment of Liver Cancer

Yahoo

Can-Fite BioPharma

hepatocellular carcinoma

Flag link:

Can-Fite's Phase II Liver Cancer Trial Approved in Europe

Can-Fite's Phase II Liver Cancer Trial Approved in Europe

Yahoo

Can-Fite BioPharma

Flag link:

Pipeline Setback at Can-Fite BioPharma, Shares Down

Pipeline Setback at Can-Fite BioPharma, Shares Down

Yahoo/Zacks.com

Can-Fite BioPharma

Flag link: